Cephalon, Inc. to Webcast R&D Day

FRAZER, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its Research and Development Day in New York City, to be held on November 10, 2009, will be webcast live on the investor relations section of its website at http://www.cephalon.com.

Cephalon's senior management will review the company's product pipeline and discuss research and development initiatives including its pipeline of biologics from its recent acquisition of Arana Therapeutics. In addition, guest speakers will present data on two investigational medications, Lupuzor(TM), for the treatment of systemic lupus erythematosus and Ception Therapeutics, Inc.'s lead compound, reslizumab, a humanized monoclonal antibody (mAb) against interleukin-5 for the treatment of pediatric eosinophilic esophagitis and eosinophilic asthma in adults. Cephalon holds an option to acquire Ception.

The presentations will be delivered on Tuesday, November 10, 2009 beginning at approximately 12:00 p.m. EST and ending at 3:00 p.m. EST. The webcast will be archived for one week following the broadcast. To access the webcast, log on to the company's website at www.cephalon.com and click on "Investors," then "Webcast." Click on the link and follow the prompts for registration and access.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL® (armodafinil) Tablets [C-IV], AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), TREANDA® (bendamustine hydrochloride) for Injection, FENTORA® (fentanyl buccal tablet) [C-II], PROVIGIL® (modafinil) Tablets [C-IV], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine hydrochloride) and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

    Contacts:
    Media:                         Investors:
    Sheryl Williams                Robert (Chip) Merritt
    610-738-6493                   610-738-6376
    swilliam@cephalon.com          cmerritt@cephalon.com